September 30, 2026 11:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
SIR row: Supreme Court to hear plea against CEC Gyanesh Kumar next week | Sambhal violence case: SC quashes key accused Mulla Afroz's NSA detention, slaps Rs 10 lakh cost on UP govt | Nandigram bypoll twist: Calcutta HC grants interim bail to Congress candidate Milan Pradhan till Oct 21 | Myanmar military airstrike horror: 49 killed, 58 injured as bombs hit crowded Rakhine market | Britain reopens refugee routes for Afghans, Palestinians as immigration and integration battle intensifies | New York Times executive shot dead: Elderly in-laws arrested amid bitter family feud over his 'trans' identity | Vijay's TVK makes Bengal entry: First party office opens in Purba Bardhaman amid state's political shake-up | SRFTI clash erupts over ABGP event: Students allege assault; BJP calls it ‘ugly face of Leftists’ | 'Asif bhai gun nikal': 17-year-old's chilling account of men posing as cops raping her in South Delhi park | Indian passport rules changed: New validity, fees for children and adults explained

AstraZeneca to invest $50 billion in US, build largest factory in Virginia amid Trump tariff threats

| @indiablooms | Jul 22, 2025, at 08:40 pm

British pharmaceutical major AstraZeneca on Tuesday unveiled a $50 billion investment plan in the United States, which includes setting up a multi-billion-dollar manufacturing facility in Virginia—its largest single investment in manufacturing to date, according to media reports.

The move comes as the Trump administration escalates pressure on foreign pharmaceutical imports through proposed steep tariffs.

According to AFP, the company anticipates that half of its global revenue will come from the US by 2030, signalling a marked strategic pivot toward the American market.

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals,” AstraZeneca CEO Pascal Soriot said in a statement.

The announcement coincides with US President Donald Trump intensifying his stance on imposing tariffs on drug imports—an area previously spared in earlier rounds of trade levies.

A White House-commissioned investigation is currently underway, and new duties could go as high as 200%, according to hints from the administration.

“For decades Americans have been reliant on foreign supply of key pharmaceutical products,” US Commerce Secretary Howard Lutnick was quoted as saying by AFP.

He added that the proposed measures are designed to “end this structural weakness” in the domestic pharmaceutical supply chain.

AstraZeneca’s Virginia facility is set to be the centrepiece of its expanded footprint in the US and mirrors a broader industry trend.

Several other global drugmakers—who had largely escaped tariffs for the last three decades—are also beginning to move investment and manufacturing to American soil.

Back in April, AstraZeneca had already revealed plans to shift part of its European manufacturing base to the US, even before the current tariff momentum took shape.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.